COCO · The Vita Coco Company, Inc. · Stock research

Current Thesis

Q2 FY26 on 2026-07-23 delivered — net sales $216.2M, +28.1% YoY, diluted EPS $0.82 against roughly $0.55 consensus, adjusted EBITDA $67.2M (31% of net sales) versus $29M (17%) a year earlier, and a full-year raise to $790–805M / $154–161M adjusted EBITDA from the late-April guide of $720–735M / $132–138M.

What has changed since the last update is the shape of the tape, not the fundamentals. On 2026-08-07 the stock closed $62.25 with RSI(14) at 27.5. On 2026-08-21 it closed $63.35 with RSI(14) at 49.9 — the oversold reading was worked off by roughly ten sessions of time and about 1.8% of price, which is repair through sideways drift rather than a reclaim. The stock sits -24.6% below the $84.02 adjusted 52-week high, with a three-month price change of -16.7%.

The narrative is saturated, dated by the 2026-07-23 reaction and unchanged by the four weeks since. An unambiguous beat, a $175M acquisition and a raised guide produced a marginal new high and then supply; the only news item inside the last 30 days is a generic aggregator list (2026-08-13, "12 Consumer Staples Stocks Moving In Thursday's After-Market Session"). Attention has drained without price recovering. What is being priced now is whether 2026 profitability is a run rate or a tariff-refund-flattered peak.

Bullish and bearish views on The Vita Coco Company, Inc.

The model's bull view on The Vita Coco Company, Inc. (COCO), in brief: Q2 FY26 (2026-07-23): net sales $216.2M, +28.1% YoY, with growth in both branded and private-label coconut water. The bear view: The 49% Q2 gross margin is not the run rate. Both cases follow in full.

Bull Case

• Q2 FY26 (2026-07-23): net sales $216.2M, +28.1% YoY, with growth in both branded and private-label coconut water.
• Diluted EPS $0.82 vs ~$0.55 consensus; net income $49.5M vs $23.0M in the year-ago quarter.
• Guidance raised twice inside one quarter — late April to $720–735M, then 2026-07-23 to $790–805M net sales and $154–161M adjusted EBITDA.
• The issuer is buying: authorization expanded by $40M to $105M, with approximately $44M repurchased through 2026-07-22, executed while the stock was near its high.
• Post-print sell-side did not blink. The five most recent published actions listed by stockanalysis.com as of 2026-08-22: Piper Sandler Buy $89 (2026-07-24), Bank of America Buy $85 (2026-07-24), Wells Fargo Buy $85 (2026-07-24), Needham Hold with no target (2026-07-24), Morgan Stanley Hold $68 (2026-07-28). Average target $83.89 across 11 analysts. No target has been cut in the four weeks since 2026-07-28 — the downward-convergence risk flagged in prior coverage has not yet been observed.
• Copra, Inc. Closed 2026-07-22 for $175M cash — a super-premium Thai Nam Hom producer, adding a price tier above the core brand and owned supply.
• Multiple compressed while earnings rose: trailing P/E 34.35 at the 2026-08-07 close, against the ~49x carried into the July print.

Bear Case

• The 49% Q2 gross margin is not the run rate. Tariff refunds contributed roughly 700bps to Q2 gross margin and ~300bps year-to-date; management's own FY26 guide is ~40%. The headline profitability that drove the July high contains a component the company has already guided away from.
• The binary came and went. It resolved bullish on every reported line on 2026-07-23 and the stock is a quarter below its post-print high a month later. Good news absorbed at a new high is distribution behaviour, and nothing since has produced a bid.
• The catalyst void is long. The Q3 FY26 date was still unannounced as of 2026-08-22; on the Q1 (2026-04-29) and Q2 (2026-07-23) cadence, a late-October print is the working estimate. That leaves roughly ten weeks with no dated company event.
• Balance-sheet strength is dated. The $279M cash, no debt figure is the Q2 close and precedes the $175M Copra outflow.
• Private-label growth cuts both ways. Mix shifting toward retailer own-brand dilutes the branded pricing-power story the multiple rests on.

Setup & Price Structure

• The ~$60 shelf — the late-April Q1 breakaway gap — is the last structure below spot. It has held on a closing basis through the entire post-print drawdown, including the 2026-08-07 low-RSI session.
• The stock has made no attempt at the mid-$70s since the print. The recovery from $62.25 to $63.35 over ten sessions with RSI moving 27.5 → 49.9 describes range repair, and a range needs a reason to break upward that the calendar does not currently supply.
• Positioning observables, stated as observables: the issuer is an active buyer under a $105M authorization; sell-side targets sit $4.65 to $25.65 above the 2026-08-21 close with zero cuts since 2026-07-28; there is no earnings date inside 30 days; retail-flow coverage clustered before the print (2026-06-03 Benzinga on IBD SwingTrader buying; 2026-05-15 Benzinga flagging RSI above 70) and has gone quiet since.
• Insider filings, read correctly: Form 4s dated 2026-08-15 show CMO Jane Prior and CCO Charles van Es each with 10,801 shares withheld at $65.21 for tax on RSU settlement. These are non-discretionary dispositions tied to vesting, and the footnote says so — they are a dated price mark inside the range, not a sale decision.

Catalyst Calendar (next 30 days)

• 2026-08-22 to 2026-09-21 — no company-confirmed event. The Q3 FY26 earnings date had not been announced as of 2026-08-22.
• ~2026-10-29 (est.), outside the window — Q3 FY26 print. First quarter without the tariff-refund benefit and first read on Copra's contribution.

Elapsed catalysts

• ~September 2026 (unconfirmed) — consumer-staples conference season. Vita Coco presented at the Goldman Sachs Global Staples Forum in May 2026, so a September appearance is plausible; no such participation was confirmed by the company as of 2026-08-22, and treating it as scheduled would be wrong. (passed 4d ago)

What Would Change Our Mind

The structure that matters is the late-April gap shelf near $60. Losing it on a weekly close below $60 fills that gap and retraces the entire post-Q1 re-rate, at which point the July beat-and-raise has been fully rejected by the market and the saturated label hardens into a broken one. Second, the margin question: Q3 FY26 gross margin printing at or under the ~40% FY guide, or management quantifying an incremental tariff cost rather than a refund, would confirm that 2026's reported profitability was a policy artifact.

What would argue the other way is equally specific: a reclaim of the mid-$70s on expanding volume, a Q3 print with gross margin holding above the ~40% guide with Copra revenue quantified, or the buyback consuming a visible share of the remaining ~$61M authorization at these levels. Absent one of those, a stock -24.6% from its high with no dated catalyst for roughly ten weeks is a waiting problem, and there is no penalty for waiting for the base to form.

Correlation Notes

• No listed coconut-water pure-play exists. Sympathy reads have to be borrowed from the wider functional-beverage complex, which imports beta that has nothing to do with coconut supply or Vita Coco's private-label book.
• Tariff policy is a direct P&L line here, not a macro overlay. The ~700bps Q2 gross-margin contribution from refunds means US import-duty rulings on Southeast Asian beverage inputs move this income statement more than they move a domestically sourced staple.
• Copra ties the story to Thai Nam Hom sourcing, adding crop, freight and FX exposure concentrated in Thailand and the Philippines.
• Private-label revenue tracks retailer own-brand programs, so shelf-reset and club-channel decisions at large grocers are a transmission channel distinct from branded beverage demand.
• Trailing P/E 34.35 at the 2026-08-07 close keeps the name in the high-multiple small-cap growth bucket, where flow rather than fundamentals sets the marginal price in a catalyst void.